Obinutuzumab and idelalisib in symptomatic patients with relapsed/refractory Waldenström macroglobulinemia

We present the results of a phase 2 study evaluating the combination of obinutuzumab + idelalisib in relapsed/refractory (R/R) Waldenström macroglobulinemia (WM). The goal was to determine the safety and efficacy of a fixed-duration chemotherapy-free treatment. During the induction phase, patients r...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Tomowiak, Cécile, Poulain, Stéphanie, Herbaux, Charles, Perrot, Aurore, Mahé, Béatrice, Morel, Pierre, Aurran, Thérèse, Tournilhac, Olivier, Leprêtre, Stéphane, Assaad, Souad, Villemagne, Bruno, Casasnovas, Olivier, Nollet, Delphine, Roos-Weil, Damien, Chevret, Sylvie, Leblond, Véronique
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8114554/
https://ncbi.nlm.nih.gov/pubmed/33961019
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003895
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky